Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Seladelpar 10 mg Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Seladelpar, Placebos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Nov 5, 2026, 1:53 AM EST
Recruiting Phase 3 Interventional

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 3 Interventional

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

NCT06060665
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 2 Interventional Results available

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

NCT02955602
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Coronado, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Nov 5, 2026, 1:53 AM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

NCT04024813
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Seladelpar, Placebo to match Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 5, 2026, 1:53 AM EST
Recruiting Phase 2 Interventional

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

NCT07841977
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Nov 5, 2026, 1:53 AM EST
Active, not recruiting Phase 3 Interventional

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 3 Interventional Results available

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
seladelpar 5-10 mg, seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 1 Interventional Results available

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions
Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 1:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT03369002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Nov 5, 2026, 1:53 AM EST